Association of Serum Lipocalin-2 Concentrations with Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis.

Dingjian Wang, Lanlan Fang, Guixia Pan
Author Information
  1. Dingjian Wang: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China. ORCID
  2. Lanlan Fang: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China.
  3. Guixia Pan: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China. ORCID

Abstract

OBJECTIVES: The purpose of this study was to explore the association of serum lipocalin-2 concentrations with psoriasis and psoriatic arthritis (PsA).
METHODS: A systematic search of studies on the association of serum lipocalin-2 concentrations with psoriasis/PsA was conducted in PubMed, Web of Science, Elsevier ScienceDirect, and Cochrane Library. Eventually, 8 eligible studies were included. The strength of association between serum lipocalin-2 concentrations and psoriasis/PsA was assessed by pooled standard mean difference (SMD) with its 95% confidence intervals (CIs).
RESULTS: A total of 8 case-control studies, consisting of 349 psoriasis/PsA patients and 258 controls, were included in the meta-analysis. This meta-analysis showed significant association between serum lipocalin-2 concentrations and psoriasis/PsA in overall population (SMD: 0.757, 95%CI = 0.588-0.926, and = 0.114; is the value for the heterogeneity test). Similar results were found in subgroup analysis by ethnicity.
CONCLUSIONS: Serum lipocalin-2 concentrations are higher in psoriasis/PsA patients than controls. However, more large-scale studies are warranted to explore the association between serum lipocalin-2 and the pathogenetic mechanisms of psoriasis/PsA.

References

  1. JAMA. 2000 Apr 19;283(15):2008-12 [PMID: 10789670]
  2. BMC Med Res Methodol. 2005 Apr 20;5:13 [PMID: 15840177]
  3. J Biol Chem. 2006 Aug 25;281(34):24138-48 [PMID: 16798734]
  4. Eur Heart J. 2009 May;30(10):1229-36 [PMID: 19329498]
  5. J Clin Epidemiol. 2009 Oct;62(10):1006-12 [PMID: 19631508]
  6. Exp Dermatol. 2011 Feb;20(2):81-7 [PMID: 21255085]
  7. Int J Biol Sci. 2011 Jan 18;7(1):74-86 [PMID: 21278918]
  8. Clin Exp Dermatol. 2012 Apr;37(3):296-9 [PMID: 22300286]
  9. Arch Dermatol Res. 2013 Mar;305(2):105-12 [PMID: 23242471]
  10. Arch Dermatol Res. 2014 Apr;306(3):239-45 [PMID: 24052155]
  11. Infect Immun. 2014 Mar;82(3):1030-5 [PMID: 24343647]
  12. J Hepatol. 2014 Jul;61(1):35-42 [PMID: 24613364]
  13. Dis Markers. 2014;2014:541709 [PMID: 24803721]
  14. J Biol Chem. 2014 Jun 13;289(24):16773-89 [PMID: 24808182]
  15. Eur J Dermatol. 2015 Apr;25(2):195-7 [PMID: 25547333]
  16. J Dermatol. 2016 Jul;43(7):785-94 [PMID: 26702876]
  17. J Invest Dermatol. 2016 Jul;136(7):1418-1428 [PMID: 26979478]
  18. J Dermatolog Treat. 2017 Mar;28(2):136-140 [PMID: 27165470]
  19. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1876-1885 [PMID: 27230733]
  20. Stat Methods Med Res. 2018 Jun;27(6):1785-1805 [PMID: 27683581]
  21. Clin Exp Dermatol. 2017 Mar;42(2):161-166 [PMID: 27925680]
  22. J Dermatol Sci. 2018 Apr;90(1):68-74 [PMID: 29395573]
  23. Oncotarget. 2017 Nov 1;9(1):1266-1278 [PMID: 29416693]
  24. Bratisl Lek Listy. 2019;120(1):65-69 [PMID: 30685995]
  25. J Immunol Res. 2019 Jan 21;2019:8171373 [PMID: 30805373]
  26. Int J Mol Sci. 2019 Mar 06;20(5):null [PMID: 30845706]
  27. Dermatol Clin. 2019 Apr;37(2):129-136 [PMID: 30850034]
  28. Postepy Dermatol Alergol. 2019 Feb;36(1):70-75 [PMID: 30858782]
  29. Int J Mol Sci. 2019 Mar 23;20(6):null [PMID: 30909615]

MeSH Term

Arthritis, Psoriatic
Biomarkers
Humans
Lipocalin-2

Chemicals

Biomarkers
Lipocalin-2

Word Cloud

Created with Highcharts 10.0.0lipocalin-2psoriasis/PsAassociationserumconcentrationsstudies0explore8includedpatientscontrolsmeta-analysis=SerumOBJECTIVES:purposestudypsoriasispsoriaticarthritisPsAMETHODS:systematicsearchconductedPubMedWebScienceElsevierScienceDirectCochraneLibraryEventuallyeligiblestrengthassessedpooledstandardmeandifferenceSMD95%confidenceintervalsCIsRESULTS:totalcase-controlconsisting349258showedsignificantoverallpopulationSMD:75795%CI588-0926114valueheterogeneitytestSimilarresultsfoundsubgroupanalysisethnicityCONCLUSIONS:higherHoweverlarge-scalewarrantedpathogeneticmechanismsAssociationLipocalin-2ConcentrationsPsoriasisPsoriaticArthritis:UpdatedMeta-Analysis

Similar Articles

Cited By